Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zotizalkib (TPX-0131) in ALK+ Advanced NSCLC
NCT04849273Phase 1Terminated
- Sponsor
- Turning Point Therapeutics, Inc.
- Start
- Jul 2021
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of zotizalkib in non-small cell lung cancer (NSCLC), sponsored by Turning Point Therapeutics, Inc. Primary endpoints: Incidence of Dose-Limiting Toxicities at 28 days and Recommended Phase 2 Dose at 24 months. Started Jul 2021; status: terminated.
02
Drugs
zotizalkib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04849273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04849273.